Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation

NEW YORK, July 12, 2017 /PRNewswire/ -- Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation

Summary

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare autoimmune disorders such as scleroderma to very common conditions such as acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control it can significantly impair the patient's quality of life. For example, patients with severe atopic dermatitis may experience mobility impairments and debilitating itching, which may interfere with daily activities. Furthermore, disease visibility can have a profoundly negative impact on patient confidence.

Dermatological conditions are some of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active condition. Although dermatological diseases are disparate in terms of their symptoms and key patient demographics, many are characterized by increased inflammation and linked by an aberrant immune response resulting in skin barrier dysfunction. Infections and dysfunctions in wound healing are further common causes of dermatological diseases.

For the past decade the majority of the therapeutic dermatology market has been saturated and highly genericized. There is a significant unmet need for more efficacious and safer treatment options, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues with the long-term use of many available treatments. Various treatment options exist within the therapy area, including topical glucocorticosteroids, retinoids, antihistamines and immunosuppressive agents, all of which are heavily genericized. The majority of marketed products within dermatology are small molecules, which account for 98.2% of all products. There are only a small number of other more novel molecule types, such as monoclonal antibodies (mAb), proteins and cell therapies, available in the market.

Overall, the dermatology pipeline is considerably innovative, owing to the advancements in understanding of the disease pathways of many skin disorders. Analysis by molecular target highlights that there is a strong degree of innovation and diversity beyond the current market landscape. There is a clear emphasis, demonstrated particularly by biologics in mid-to-late stage clinical development, on developing effective targeted therapies aimed at key molecules in disease pathology, which represents an innovative approach that will benefit the market in the coming years. On the other hand, therapeutic molecular target classes that are already present in the market – such as histamine receptors, retinoic acid receptors, glucocorticoid receptors, and tumor necrosis factor – also maintain a presence in the pipeline, which indicates that developing established therapeutic classes remains attractive.

The report "Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation" is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Specifically, this report provides the following analysis -
- Visualize the composition of the dermatology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
- Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating dermatological diseases, including rare conditions.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: inflammatory diseases, infectious diseases, and wounds/scars. Promising targets have been reviewed in greater detail.
- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.

Companies mentioned in this report: Bristol-Myers Squibb, Pfizer, Nimbus Therapeutics, Sareum, Genentech, Portola Pharmaceuticals, Oncostellae.

Scope

- With 961 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future dermatology market?
- There are 197 first-in-class products in the dermatology pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
- The majority of first-in-class products are in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
- A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy

- Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the dermatology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
- Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating dermatological diseases, including rare conditions.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: inflammatory diseases, infectious diseases, and wounds/scars. Promising targets have been reviewed in greater detail.
- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.
Read the full report: http://www.reportlinker.com/p04978351/Frontier-Pharma-Dermatology-Intracellular-Signal-Transducers-and-Cytokine-Signaling-Molecules-Dominate-Pipeline-and-First-in-Class-Innovation.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/frontier-pharma-dermatology---intracellular-signal-transducers-and-cytokine-signaling-molecules-dominate-pipeline-and-first-in-class-innovation-300487275.html

SOURCE Reportlinker